THE FINANCIAL SUPERVISION AUTHORITY HAS APPROVED TERVEYSTALO'S BASE PROSPECTUS

SUOMEN TERVEYSTALO OYJ		STOCK EXCHANGE RELEASE
September 5, 2008 at 4.00 p.m.


THE FINANCIAL SUPERVISION AUTHORITY HAS APPROVED TERVEYSTALO'S REGISTRATION
DOCUMENT 

The Financial Supervision Authority has on September 5, 2008, approved Suomen
Terveystalo Oyj's (”The Company”) Registration Document which, in accordance
with the Finnish Securities Markets Act, contains information on the Company,
its operations, and financial position (“Registration Document”). The
Registration Document is valid for 12 months after its publication. 

From September 5, 2008, the Registration Document is available in Finnish on
the Company's website at www.terveystalo.com under the Investors section. 

The Registration Document published today in Finnish in electronic format
contains, for instance the following previously unpublished information on the
Company: 

1) On June 30, 2008, approximately 85 percent of Company loans carried variable
interest rates. Taking into account the effect of interest rate derivatives,
the share of variable interest rate loans was approximately 36 percent. 

2) An increase of one percentage point in interest rates would increase the
Company's annual interest expense for interest-bearing liabilities by
approximately EUR 1.4 million. Tax effect has not been considered in the
sensitivity analysis. 

3) The Company does not apply hedge accounting as set out in IAS 39 to its
interest rate derivatives. Interest rate derivatives are recognized at fair
value through the income statement and accordingly, the financial income and
expenses may vary considerably between financial years. An increase of one
percentage point in interest rates would have increased the fair value of the
Company´s derivative instruments through the income statement by approximately
EUR 1.2 million as at June 30, 2008. Tax effect has not been considered in the
sensitivity analysis. 

4) On June 30, 2008, the Company's ratio between interest-bearing net debt and
the operating margin was 6.31. Interest bearing net debt amounted to EUR 155.4
million on June 30, 2008 (EUR 9.1 million in the comparison period on June 30,
2007). Interest bearing net debt = Non-current interest-bearing debt + current
interest-bearing liabilities - financial liquid assets recognised at fair value
through profit or loss -liquid assets. 
 
5) During the period January 1 - June 30, 2008, the Company has recognized
credit losses amounting to EUR 23,668.29, and impairment losses on accounts
receivables amounting to EUR 250,000.00. 

6) The Company's EBITDA during the period January 1 - June 30, 2008, was EUR
16.6 million (EUR 8.0 million in the comparison period January 1 - June 30,
2007). EBITDA of net sales amounted to 15.3 percent during January 1 - June 30,
2008 (13.9% in the comparison period January 1 - June 30, 2007). EBITDA =
Operating profit plus depreciation and impairment; EBITDA of turnover % =
(Operating profit plus depreciation and impairment) / Turnover * 100%. 

7) The turnover of the central laboratory operations divested by the Company in
February 2008 consisted mainly of internal sales within Terveystalo Group. The
effect of the divestment on the 2008 turnover is approximately EUR -0.8 million
and on earnings approximately EUR +0.1 million at Group level. The turnover of
the central laboratory operations in the consolidated financial statement for
2007 was approximately EUR 0.9 million and operating loss was approximately EUR
0.1 million. 

8) The effect on 2007 turnover of the divestment of business operations of
Helsingin Hammaslaseri Oy by the Company's subsidiary in May 2007 was EUR -0.7
million at Group level and EUR +0.1 million on Group profit. 

9) The Group's total sales during the period January 1 - June 30, 2008, was EUR
149.4 million (EUR 95.5 million in the comparison period January 1 - June 30,
2007). 

10) After the interim report was published on August 14, 2008, the Company has
raised new interest-bearing debt by a total of EUR 10.0 million in August 2008.
On August 31, 2008, EUR 1.1 million of the loan is current and EUR 8.9 million
is non-current. Taking into account the new interest-bearing loan, installments
amounting to approximately EUR 32.8 million will mature between July 1, 2008,
and June 30, 2009. 

11) The Company has agreed with the main financers that if the Board decides to
carry out the share issue, a minimum of 50 percent of the funds from the issue
will be used for an extra repayment of non-current loans. 

12) On June 30, 2008, the Company's interest-bearing debt consists of following
items: Capital loans EUR 1.7 million, loans from financial institutions and
pension loans EUR 145.8 million and finance lease liabilities EUR 15.4 million. 

13) The Company's interest-bearing debt will mature as follows: EUR 21.7
million in 2008, EUR 24.8 million in 2009, EUR 23.4 million in 2010, EUR 21.6
million in 2011, EUR 76.1 million in 2012, and EUR 3.4 million in 2013 and
later. 

14) By September 5, 2008, the Company had EUR 0.5 million contingent purchase
price considerations related to completed acquisitions. Of the contingent
purchase price considerations, an estimated EUR 0.3 million will mature during
2008 and the rest during the year 2009. The contingent purchase price
considerations are mainly based on the earnings development of the acquired
units and the maximum amount is limited. All contingent purchase price
considerations have been recorded at their probable value as liabilities in the
Company's balance sheet. The Company has not made any acquisitions between
January 1 and September 5, 2008. 

15) Medivire Työterveyspalvelut Oy's (Suomen Terveystalo Työterveys Oy since
December 3, 2007) financial statements and annual reports for the financial
periods ended on December 31, 2005, December 31, 2006, and December 31, 2007,
have been incorporated by reference in the Registration Document. 

16) The Registration Document includes an unaudited and more extensive pro
forma financial information which is presented only for illustrative purposes
to demonstrate what Terveystalo Group's operating result and financial position
would have been if the Medivire Työterveyspalvelut Oy acquisition completed on
August 31, 2007, would have been completed on January 1, 2007. 

17) The Registration Document includes more extensive information on related
party transactions than have been presented previously. 

18) The Registration Document includes previously unpublished information on
the allocation of management option rights 2008A to the Managing Director and
Management Team. 

Helsinki, September 5, 2008

SUOMEN TERVEYSTALO OYJ
Martti Kiuru, Managing Director

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
Managing Director Martti Kiuru, tel. +358 30 633 1629,
martti.kiuru@terveystalo.com 
CFO Jukka Yli-Hankala, tel. +358 30 633 1743, jukka.yli-hankala@terveystalo.com

This release is available at http://www.terveystalo.com

Terveystalo:
Terveystalo is Finland's leading healthcare service company, offering versatile
healthcare, occupational healthcare, diagnostics and hospital services. The
company has more than 100 units around the country. Terveystalo, which was
founded in 2001, has grown strongly. The company share is listed on the OMX
Nordic Exchange Helsinki under the code SUT1V. 

DISTRIBUTION:
OMX Nordic Exchange Helsinki
Principal media